| Today's Big NewsJul 24, 2023 |
|
October 16-18, 2023 | Boston, MA
This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape. 
|
|
| By James Waldron Gilead’s $4.9 billion bet on Forty Seven has run into further trouble, with the Big Pharma pulling the plug on its myelodysplastic syndromes (MDS) ambitions for the lead CD47 asset from that deal in the face of a disappointing phase 3 trial. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron Pfizer is walking away from a sickle cell disease and beta thalassemia licensing deal with Syros Pharmaceuticals that it inherited from its takeover of Global Blood Therapeutics last year. |
By Max Bayer Roche is betting more than $300 million in immediate cash that Alnylam's phase 2-stage hypertension med is a winner. Roche will have exclusive ex-US rights to the drug and both companies will co-commercialize and share profits inside the US. |
By Max Bayer Amgen's difficult streak of lupus candidates persisted after Horizon's mid-stage asset failed a phase 2 trial. The newly-acquired company is continuing to study daxdilimab in other forms of the condition as well as alopecia. |
By James Waldron Bavarian Nordic has crashed out of the respiratory syncytial virus vaccine race, with a phase 3 failure sending the company’s plans—and stock price—into a tailspin. |
By James Waldron Kodiak Sciences has blamed an “unexpected increase in cataracts” as a reason for the failure of a pair of phase 3 trials that have led the biotech to drop its antibody biopolymer conjugate and halved its share price |
By James Waldron Infinity Pharmaceuticals' merger saga has rumbled on almost as long as its namesake, but finally the biotech has closure—just not the way it wanted. |
By Fraiser Kansteiner Pfizer on Friday said it kicked off “immediate efforts” to provide relief and repair to the damage caused to its manufacturing facility in Rocky Mount, North Carolina. It noted crews are working around the clock to restore power, assess the structural integrity of the building and to relocate finished medicines to nearby sites for storage. |
By Ben Adams We waited years for working RSV vaccines and in 2023, in the space of just a few weeks, we had two come all at once, with another on the horizon and a fresh approval for an RSV prevention med. |
By Conor Hale The motorized ES system helps stabilize the surgeon’s direct manual control of their instrument, with the goal of reducing natural hand tremors. |
By Ben Adams Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry's reputation in 2022 compared to the previous year. Nevertheless, they continue to identify two major concerns for respiratory diseases—pricing and access to medicines—which remain unresolved. |
By Heather Landi The healthcare industry has felt the fallout from the economic downturn. Healthcare technology and digital health companies continue to cut jobs in the face of market uncertainty and the need to restructure operations. Here are the latest industry layoffs. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
